A randomized, open label, active controlled study of AMG 162 [denosumab] in subjects with advanced cancer currently being treated with intravenous bisphosphonates

Trial Profile

A randomized, open label, active controlled study of AMG 162 [denosumab] in subjects with advanced cancer currently being treated with intravenous bisphosphonates

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jan 2011

At a glance

  • Drugs Denosumab (Primary) ; Pamidronic acid; Zoledronic acid
  • Indications Advanced breast cancer; Bone resorption; Breast cancer; Cancer metastases; Malignant melanoma; Multiple myeloma; Prostate cancer; Solid tumours
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 06 Jan 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
    • 06 Jan 2011 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top